Key result
During an 8 to 9 year follow-up, 11 of 27 children immunized with 4 doses of inactivated measles vaccine showed clinical or serological signs of wild measles infection.
Why the study?
What is the long-term clinical and serological outcome of children immunized with formalin-inactivated measles vaccine or purified hemagglutinin?
Cohort (n=27)
What is the long-term clinical and serological outcome of children immunized with formalin-inactivated measles vaccine or purified hemagglutinin?
HI antibodies of a certain minimal concentration can block the replication of vaccine virus even in the absence of non-HI HLI antibodies, suggesting future vaccines should include both hemagglutinin and hemolysin.
This is the authors' abstract. We don't add key points for this paper.
Children immunized with 4 doses of formalin-inactivated vaccine and/or purified hemagglutinin prepared from Tween 80-ether (TE) treated material were subjected to a follow-up 8-9 years after the last dose of vaccine. 11 out of 27 children had clinical and/or serological signs of infections with wild measles virus during the 8 to 9 years post-booster period. 10 out of the 11 children with infections had non-hemagglutinating-inhibiting (HI) hemolysis-inhibiting (HLI) antibodies demonstrable in their sera after removal of HI antibodies by absorption with TE antigen. In contrast 13 out of 16 vaccinees without detectable signs of infection lacked non-HI HLI antibodies. 10 out of these 13 children were vaccinated with further attenuated live measles virus. There were no clinical reactions to faccination. 4 vaccinees with low pre-vaccination HI antibody titers showed significant rises of antibody titers including non-HI HLI antibodies. In the remaining children no take of the live vaccine could be demonstrated. Thus HI antibodies of a certain minimal concentration can block the replication of vaccine virus even in the absence of non-HI HLI antibodies. However, since it will be difficult to establish these conditions by sue of available inactivated vaccines it is recommended that future vaccine products should include both major virus envelope surface components, the hemagglutinin and the hemolysin.
Answers are grounded in this paper and cite their sources.
May indicate inadequate long-term protection from inactivated measles vaccine; leaves open optimal antigen requirements for durable immunity.
No takes yet. Share an insight, caveat, or question.
Norrby et al. (1976) conducted a cohort in Measles vaccination (n=27). Formalin-inactivated vaccine and/or purified hemagglutinin was evaluated on Clinical and/or serological signs of infections with wild measles virus. During an 8 to 9 year follow-up, 11 of 27 children immunized with 4 doses of inactivated measles vaccine showed clinical or serological signs of wild measles infection.
Synapse has enriched 10 related papers. Consider them for comparative context: